ARKG250103C21500
- 3.02
- 0.000.00%
ARK Genomic Revolution ETF Newsroom
Cathie Wood's Ark Invest Books Profits On Hot AI Stock Palantir, Sells Bitcoin ETF Shares As BTC Starts 2025 On A Positive Note
Natera Shares Are Trading Higher After Canaccord Genuity Raised Its Price Target on the Stock From $165 to $180.
Trending Industry Today: ARK Genomic Revolution ETF Leads Gains In ARK ETFs Stocks
Nio, Unity Software And Other Big Stocks Moving Higher On Thursday
Mizuho CEO Sees Global Boom in M&A After Trump Takes Office
2024's 'Biggest Loses' That Could See Reversal in 2025
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
JMP Securities Reiterates Market Outperform on CRISPR Therapeutics, Maintains $86 Price Target
Trending Industry Today: ARK Genomic Revolution ETF Leads Losses In ARK ETFs Stocks
Adaptive Biotechnologies Analyst Ratings
Twist Bioscience Analyst Ratings
Natera Analyst Ratings
Natera Announces Enrollment Of First Patients In SAGITTARIUS A Randomized Phase III Clinical Trial In Colon Cancer; ~700-900 Patients Expected To Be Enrolled Across More Than 20 Sites
Cathie Wood's Ark Invest Trims Tesla Exposure Amid Searing Rally, Sells $21.8M Worth Of Stock — Bets On This AI Medical Company
Editas Cut to Equal Weight by Wells Fargo Over Reni-cel Positioning
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target
Recursion Pharmaceuticals Analyst Ratings
CareDx Announced That CareDx Will Partner With TC BioPharm To Perform Pharmacokinetic Analysis Using Its AlloCell Solution In The Achieve Clinical Trial
Top 3 Health Care Stocks That May Collapse This Quarter
10 Health Care Stocks With Whale Alerts In Today's Session